Brainomix e-Lung Biomarkers are Prognostic & Outperform FVC in the Serial Assessment of Patients with Fibrotic Lung Disease

Time: 11:45 am
day: Day One Track B AM


• FVC as the ‘gold’ standard clinical trial endpoint is variable and may in insensitive to treatment efficacy

• Brainomix e-Lung biomarkers provide robust assessment of serial change and have been validated in both IPF and nonIPF cohorts

• Imaging biomarkers may hold the key to successful delivery of the next generation of ILD clinical trial